Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Advisory Committee Set To Review Cardiovascular Risk Assessment For Obesity Drugs

This article was originally published in The Pink Sheet Daily

Executive Summary

Recent guidance on Orexigen’s Contrave could provide clues about how the agency is leaning on drugs in the highly safety conscious obesity category. New analysis of SCOUT data for Abbott’s withdrawn Meridia (sibutramine) could crop up in the discussion, former panelist says.

Advertisement

Related Content

Alzheimer’s R&D In Brief: Roche’s Crenezumab Misses Endpoints, Novartis Plans Large New Genetic Study
Lorcaserin Re-Review Expected To Address Risk/Benefit Trade-offs, Rat Tumors
Financings Of The Fortnight Puts On The Weight
Qnexa REMS Should Deter Off-Label Use Of Components, But Not Place Undue Burden
FDA Says Qnexa Needs CV Outcome Trial, Asks Cmte. To Consider Pre- Or Post-Approval Timeframe
With SPA Finalized, Orexigen To Begin CV Outcomes Study For Contrave In Second Quarter
Regulatory Update For Qnexa Could Signal A Change In The Obesity Landscape
Arena Ready For FDA To Reconsider Weight-Loss Drug Lorcaserin
Obesity Drugs Go Back To The Drawing Board; FDA To Hold Advisory Cmte On CV Risk
REMS Cannot Save Abbott's Obesity Drug Meridia In Face Of Cardiovascular Issues

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS073729

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel